EP4414031A3 - Glp-1 receptor agonists in dementia - Google Patents

Glp-1 receptor agonists in dementia Download PDF

Info

Publication number
EP4414031A3
EP4414031A3 EP24175772.3A EP24175772A EP4414031A3 EP 4414031 A3 EP4414031 A3 EP 4414031A3 EP 24175772 A EP24175772 A EP 24175772A EP 4414031 A3 EP4414031 A3 EP 4414031A3
Authority
EP
European Patent Office
Prior art keywords
glp
receptor agonists
dementia
semaglutide
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24175772.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4414031A2 (en
Inventor
Sarah FRIEDRICH
Charlotte Christine Thim HANSEN
Lotte Bjerre Knudsen
Anna SECHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73172681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4414031(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP4414031A2 publication Critical patent/EP4414031A2/en
Publication of EP4414031A3 publication Critical patent/EP4414031A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP24175772.3A 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia Pending EP4414031A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19207501 2019-11-06
EP20186623 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia
EP20803489.2A EP4054620B1 (en) 2019-11-06 2020-11-05 Semaglutide in the treatment of alzheimer's dementia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP20803489.2A Division EP4054620B1 (en) 2019-11-06 2020-11-05 Semaglutide in the treatment of alzheimer's dementia

Publications (2)

Publication Number Publication Date
EP4414031A2 EP4414031A2 (en) 2024-08-14
EP4414031A3 true EP4414031A3 (en) 2025-02-05

Family

ID=73172681

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24175772.3A Pending EP4414031A3 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia
EP20803489.2A Active EP4054620B1 (en) 2019-11-06 2020-11-05 Semaglutide in the treatment of alzheimer's dementia

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20803489.2A Active EP4054620B1 (en) 2019-11-06 2020-11-05 Semaglutide in the treatment of alzheimer's dementia

Country Status (19)

Country Link
US (4) US20220280612A1 (sr)
EP (2) EP4414031A3 (sr)
JP (2) JP7670698B2 (sr)
KR (1) KR20220110731A (sr)
CN (1) CN114728042A (sr)
AU (1) AU2020377469A1 (sr)
BR (1) BR112022007721A2 (sr)
CA (1) CA3154744A1 (sr)
ES (1) ES2984177T3 (sr)
HR (1) HRP20241052T1 (sr)
HU (1) HUE067514T2 (sr)
IL (1) IL291876A (sr)
MA (1) MA57599B1 (sr)
MX (1) MX2022004779A (sr)
PH (1) PH12022550842A1 (sr)
PL (1) PL4054620T3 (sr)
RS (1) RS65780B1 (sr)
TW (2) TW202519256A (sr)
WO (1) WO2021089678A1 (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728042A (zh) 2019-11-06 2022-07-08 诺和诺德股份有限公司 用于痴呆的glp-1受体激动剂
WO2021154591A1 (en) * 2020-01-30 2021-08-05 Eli Lilly And Company Therapeutic uses of dulaglutide
US20240050531A1 (en) * 2020-12-16 2024-02-15 The Chinese University Of Hong Kong A method for reversing aging brain functional decline
KR20240123816A (ko) 2021-12-02 2024-08-14 쾨벤하운스 유니버시테트 퇴행성 신경 질환의 치료를 위한 펩티드-약물 접합체
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
WO2017112889A1 (en) * 2015-12-23 2017-06-29 The Johns Hopkins University Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
CA2455963C (en) 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
NZ565535A (en) 2005-06-30 2011-03-31 Ipsen Pharma Sas GLP-1 pharmaceutical compositions
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2066337A2 (en) 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
KR101081149B1 (ko) 2006-09-07 2011-11-07 에미스페어 테크놀로지스, 인코포레이티드 Ｓｎａｃ(살카프로제이트 나트륨)의 제조 방법
CN104327182B (zh) 2009-12-16 2020-04-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX345501B (es) * 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
HRP20251088T1 (hr) * 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CN114728042A (zh) 2019-11-06 2022-07-08 诺和诺德股份有限公司 用于痴呆的glp-1受体激动剂
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
WO2017112889A1 (en) * 2015-12-23 2017-06-29 The Johns Hopkins University Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDRE F BATISTA ET AL: "The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease : Liraglutide protects memory, insulin receptors, and synapses", THE JOURNAL OF PATHOLOGY, vol. 245, no. 1, 2 April 2018 (2018-04-02), pages 85 - 100, XP055682460, ISSN: 0022-3417, DOI: 10.1002/path.5056 *
LIPING ZHANG ET AL: "Semaglutide is Neuroprotective and Reduces [alpha]-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease", JOURNAL OF PARKINSON'S DISEASE, vol. 9, no. 1, 5 February 2019 (2019-02-05), NL, pages 157 - 171, XP055767444, ISSN: 1877-7171, DOI: 10.3233/JPD-181503 *
STEPHEN N. GOMPERTS,: "Lewy Body Dementias : Dementia With Lewy Bodies and Parkinson Disease Dementia", CONTINUUM - LIFELONG LEARNING IN NEUROLOGY: THE OFFICIAL CME JOURNAL OF THE AMERICAN ACADEMY OF NEUROLOGY, vol. 22, no. 2, Dementia, 1 April 2016 (2016-04-01), US, pages 435 - 463, XP055767450, ISSN: 1080-2371, DOI: 10.1212/CON.0000000000000309 *
WATSON KATHLEEN T ET AL: "Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease", BEHAVIOURAL BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 356, 9 August 2018 (2018-08-09), pages 271 - 278, XP085492161, ISSN: 0166-4328, DOI: 10.1016/J.BBR.2018.08.006 *
YAN YANG ET AL: "Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes1", JOURNAL OF ALZHEIMER'S DISEASE, vol. 37, no. 3, 24 September 2013 (2013-09-24), NL, pages 637 - 648, XP055682486, ISSN: 1387-2877, DOI: 10.3233/JAD-130491 *
ZHANG LIPING ET AL: "Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model", NEUROPEPTIDES, CHURCHILL LIVINGSTONE, GB, vol. 71, 11 July 2018 (2018-07-11), pages 70 - 80, XP085482793, ISSN: 0143-4179, DOI: 10.1016/J.NPEP.2018.07.003 *

Also Published As

Publication number Publication date
EP4414031A2 (en) 2024-08-14
KR20220110731A (ko) 2022-08-09
US12539326B2 (en) 2026-02-03
TW202519256A (zh) 2025-05-16
EP4054620B1 (en) 2024-05-29
JP2023500032A (ja) 2023-01-04
CN114728042A (zh) 2022-07-08
JP7670698B2 (ja) 2025-04-30
EP4054620C0 (en) 2024-05-29
US20230302094A1 (en) 2023-09-28
JP2025027130A (ja) 2025-02-26
AU2020377469A1 (en) 2022-04-28
WO2021089678A1 (en) 2021-05-14
HRP20241052T1 (hr) 2024-11-08
BR112022007721A2 (pt) 2022-07-12
US20240207364A1 (en) 2024-06-27
CA3154744A1 (en) 2021-05-14
US20220280612A1 (en) 2022-09-08
TWI890704B (zh) 2025-07-21
MX2022004779A (es) 2022-06-14
MA57599B1 (fr) 2024-06-28
PL4054620T3 (pl) 2024-10-14
PH12022550842A1 (en) 2023-10-09
EP4054620A1 (en) 2022-09-14
ES2984177T3 (es) 2024-10-29
TW202118509A (zh) 2021-05-16
IL291876A (en) 2022-06-01
HUE067514T2 (hu) 2024-10-28
US20250099549A1 (en) 2025-03-27
RS65780B1 (sr) 2024-08-30

Similar Documents

Publication Publication Date Title
EP4414031A3 (en) Glp-1 receptor agonists in dementia
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
Tsiodras et al. The HIV-1/HAART associated metabolic syndrome–novel adipokines, molecular associations and therapeutic implications
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY198587A (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
HRP20201069T1 (hr) Primjena tasimelteona pod uvjetima natašte
MX2020001342A (es) Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
WO2020009740A3 (en) Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
JP2018503644A5 (sr)
MX2020011474A (es) Nuevo tratamiento de enfermedades pulmonares intersticiales.
DK1883387T3 (da) Beholder til flydende medikamenter, der skal administreres
MXPA05012773A (es) Metodo para tratar los sintomas del sindrome premenstrual.
WO2015107428A3 (en) Lipidated peptides for lowering blood glucose
WO2019241742A8 (en) Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
AU2019253577A1 (en) Oxytocin compositions and methods of use
EP4406605A3 (en) Methods and pharmaceutical compositions for treating and preventing acute respiratory distress syndrome associated with viral infections
WO2018065917A3 (en) A synthetic pulmonary surfactant composition for treating lung conditions
MX2022006045A (es) Metodos de administracion de voxelotor.
WO2019244014A3 (en) New use of inhibitors of monoamine oxidase type b
EP4588511A3 (en) Intestinal alkaline phosphatase-based treatments of metabolic disorders
PH12018500889A1 (en) Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine
Tahan et al. “If a fake friend stays in your vodkabulary as a stem friend”: Granulocyte colony-stimulating factor promoted stem cell therapy in severe alcoholic hepatitis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 4054620

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0025000000

Ipc: A61K0038260000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20241010BHEP

Ipc: A61K 38/26 20060101AFI20241010BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20250102BHEP

Ipc: A61K 38/26 20060101AFI20250102BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17P Request for examination filed

Effective date: 20250805

RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20250805

Extension state: TN

Effective date: 20250805

17Q First examination report despatched

Effective date: 20250905